Literature DB >> 12694657

Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma.

Ritsuto Fujiwaki1, Kohji Iida, Kentaro Nakayama, Haruhiko Kanasaki, Kohkichi Hata, Hidetaka Katabuchi, Hitoshi Okamura, Kohji Miyazaki.   

Abstract

OBJECTIVE: Our purpose was to determine the clinical significance of interleukin-1 receptor antagonist (IL-1ra), which is an endogenous inhibitor cytokine of IL-1, in patients with cervical carcinoma.
METHODS: Tissue IL-1ra expression and serum IL-1ra level were examined by enzyme-linked immunosorbent assay (ELISA), Western blotting, and immunohistochemistry in normal controls and patients with cervical carcinoma.
RESULTS: Tissue IL-1ra protein level by ELISA was significantly higher in squamous cell carcinoma (n = 9) than in the normal cervix (n = 7) and adenocarcinoma (n = 3). Western blotting confirmed the main presence of intracellular IL-1ra type 1 in squamous cell carcinoma. Immunohistochemistry demonstrated significant IL-1ra expression only in tumor cells of squamous cell carcinoma. Elevation of serum IL-1ra level was found in patients with squamous cell carcinoma (n = 38) compared to normal women (n = 13), but not in patients with adenocarcinoma (n = 9). Although serum IL-1ra level did not correlate with clinical stage or any other tumor marker, high serum IL-1ra level was associated with pelvic lymph node metastasis and poor prognosis in patients with squamous cell carcinoma. On the other hand, these results were not obtained in patients with cervical adenocarcinoma.
CONCLUSION: IL-1ra may play important roles in local and general malignant behaviors in patients with cervical squamous cell carcinoma, and measurement of serum IL-1ra level may be useful in predicting patient survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694657     DOI: 10.1016/s0090-8258(02)00154-3

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.

Authors:  Maryse Dagenais; Jeremy Dupaul-Chicoine; Todd Douglas; Claudia Champagne; Alexandre Morizot; Maya Saleh
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Circulating IL-1beta levels, polymorphisms of IL-1B, and risk of cervical cancer in Chinese women.

Authors:  Nianfeng Qian; Xiaojun Chen; Suping Han; Fulin Qiang; Guangfu Jin; Xiaoyi Zhou; Jing Dong; Xinru Wang; Hongbing Shen; Zhibin Hu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-11       Impact factor: 4.553

Review 3.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

4.  Comparative genomic analyses identify common molecular pathways modulated upon exposure to low doses of arsenic and cadmium.

Authors:  Margaret Ann Benton; Julia E Rager; Lisa Smeester; Rebecca C Fry
Journal:  BMC Genomics       Date:  2011-04-01       Impact factor: 3.969

5.  Reduced Expression of IL-1β and IL-18 Proinflammatory Interleukins Increases the Risk of Developing Cervical Cancer.

Authors:  Jose Anibal Matamoros; Maria Isabel Ferreira da Silva; Patrícia Muniz Mendes Freire de Moura; Maria da Conceição Gomes Leitão; Eliane Campos Coimbra
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01

6.  Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.

Authors:  Zhenyu Xie; Xin Li; Yuzhen He; Song Wu; Shiyue Wang; Jianjian Sun; Yuchen He; Yu Lun; Shijie Xin; Jian Zhang
Journal:  BMC Cancer       Date:  2020-11-25       Impact factor: 4.430

7.  Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist.

Authors:  Ming-Ling Tsai; Chi-Ting Horng; Show-Li Chen; Xiao Xiao; Chih-Hung Wang; Yeou-Ping Tsao
Journal:  Mol Vis       Date:  2009-08-08       Impact factor: 2.367

8.  PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.

Authors:  Ghaneya Al-Khadairi; Adviti Naik; Remy Thomas; Boshra Al-Sulaiti; Shaheen Rizly; Julie Decock
Journal:  J Transl Med       Date:  2019-01-03       Impact factor: 5.531

Review 9.  IL-1/IL-1R Signaling in Head and Neck Cancer.

Authors:  Sven E Niklander; Craig Murdoch; Keith D Hunter
Journal:  Front Oral Health       Date:  2021-08-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.